Torthaí cuardaigh - Paulina Selaru

  • 1 - 11 toradh as 11 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

    Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers de réir Yazdi K. Pithavala, Warren Tong, Janessa Mount, Sadayappan V. Rahavendran, May Garrett, Brian Hee, Paulina Selaru, Nenad Sarapa, Karen J. Klamerus

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Acute Hemodynamic Effects of Conivaptan, a Dual V <sub>1A</sub> and V <sub>2</sub> Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

    Acute Hemodynamic Effects of Conivaptan, a Dual V <sub>1A</sub> and V <sub>2</sub> Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure de réir James E. Udelson, William Smith, G Hendrix, Christopher A. Painchaud, Maha M Ghazzi, Ignatius Thomas, Jalal K. Ghali, Paulina Selaru, F Chanoine, Milton L. Pressler, Marvin A. Konstam

    Foilsithe / Cruthaithe 2001
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

    Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer de réir Silvia Novello, Giorgio V. Scagliotti, Rafael Rosell, Mark A. Socinski, Julie R. Brahmer, J. Atkins, Cinta Pallarés, R Burgess, L. Tye, Paulina Selaru, Edward Wang, Richard C. Chao, Ramaswamy Govindan

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

    Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC de réir S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett, Yiyun Tang, D.-W. Kim, Gregory A. Otterson, Lucio Crinò, Paulina Selaru, D. P. Cohen, Jeffrey W. Clark, Gregory J. Riely

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer de réir Yi‐Long Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Byoung Chul Cho, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang, Elizabeth T. Masters, Paulina Selaru, Tony Mok

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

    Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer de réir Mark A. Socinski, Silvia Novello, Julie R. Brahmer, Rafael Rosell, José Miguel Sánchez, Chandra P. Belani, Ramaswamy Govindan, James N. Atkins, Heidi H. Gillenwater, Cinta Pallarés, L. Tye, Paulina Selaru, Richard C. Chao, Giorgio V. Scagliotti

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

    Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases de réir Daniel B. Costa, Alice T. Shaw, Sai‐Hong Ignatius Ou, Benjamin Solomon, Gregory J. Riely, Myung‐Ju Ahn, Caicun Zhou, S. Martin Shreeve, Paulina Selaru, Anna Polli, Patrick Schnell, Keith D. Wilner, Robin Wiltshire, D. Ross Camidge, Lucio Crinò

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

    A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) de réir Harry J.M. Groen, Mark A. Socinski, Francesco Grossi, Erzsébet Juhász, Cesare Gridelli, Paul Baas, Charles Butts, Ewa Chmielowska, Tiziana Usari, Paulina Selaru, Charles S. Harmon, James A. Williams, Feng Gao, L. Tye, Richard C. Chao, George R. Blumenschein

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

    Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial de réir Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczęsna, János Strausz, А. Н. Махсон, Martin Reck, Rafal Wierzbicki, István Albert, Michael Thomas, José Elias Miziara, Zsolt Pápai, Nina Karaseva, Sumitra Thongprasert, E. Dalmau, Joachim von Pawel, Ke Zhang, Paulina Selaru, L. Tye, Richard C. Chao, Ramaswamy Govindan

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

    Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study de réir Carlo Gambacorti‐Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin‐Seok Ahn, J. Thaddeus Beck, W. Jeffrey Edenfield, Yuankai Shi, Matthew H. Taylor, Kenji Tamura, Brian A. Van Tine, Shang‐Ju Wu, Jolanda Paolini, Paulina Selaru, Tae Min Kim

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

    Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis de réir Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, Gregory J. Riely, Justin F. Gainor, Jeffrey A. Engelman, Geoffrey I. Shapiro, Daniel B. Costa, Sai‐Hong Ignatius Ou, Mohit Butaney, Ravi Salgia, Robert G. Maki, Marileila Varella‐Garcia, Robert C. Doebele, Yung‐Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, A. John Iafrate, D. Ross Camidge

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: